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Cancer-Initiating Cells from Colorectal Cancer Patients
Escape from T Cell–Mediated Immunosurveillance In Vitro
through Membrane-Bound IL-4
Andrea Volonte´,* Tiziano Di Tomaso,*,1 Michela Spinelli,* Matilde Todaro,†
Francesca Sanvito,‡ Luca Albarello,‡ Massimiliano Bissolati,x Luca Ghirardelli,x
Elena Orsenigo,x Soldano Ferrone,{ Claudio Doglioni,‡ Giorgio Stassi,† Paolo Dellabona,‖
Carlo Staudacher,x Giorgio Parmiani,* and Cristina Maccalli*
Cancer-initiating cells (CICs) that are responsible for tumor initiation, propagation, and resistance to standard therapies have been
isolated from human solid tumors, including colorectal cancer (CRC). The aim of this study was to obtain an immunological profile
of CRC-derived CICs and to identify CIC-associated target molecules for T cell immunotherapy. We have isolated cells with CIC
properties along with their putative non-CIC autologous counterparts from human primary CRC tissues. These CICs have been
shown to display “tumor-initiating/stemness” properties, including the expression of CIC-associated markers (e.g., CD44, CD24,
ALDH-1, EpCAM, Lgr5), multipotency, and tumorigenicity following injection in immunodeficient mice. The immune profile of
these cells was assessed by phenotype analysis and by in vitro stimulation of PBMCs with CICs as a source of Ags. CICs, compared
with non-CIC counterparts, showed weak immunogenicity. This feature correlated with the expression of high levels of immu-
nomodulatory molecules, such as IL-4, and with CIC-mediated inhibitory activity for anti-tumor T cell responses. CIC-associated
IL-4 was found to be responsible for this negative function, which requires cell-to-cell contact with T lymphocytes and which is
impaired by blocking IL-4 signaling. In addition, the CRC-associated Ag COA-1 was found to be expressed by CICs and to
represent, in an autologous setting, a target molecule for anti-tumor T cells. Our study provides relevant information that may
contribute to designing new immunotherapy protocols to target CICs in CRC patients. The Journal of Immunology, 2014, 192:
523–532.
R
ecent studies have shown that human solid tumors, in-
cluding colorectal cancer (CRC), include, among the
heterogeneous cell populations, a small subset of cells
defined as cancer-initiating cells (CICs) (1–3). This cell subpop-
ulation can self-renew; can generate cells that exhibit diverse
degrees of differentiation; and, upon transplantation into immu-
nodeficient mice, can give rise to tumors that resemble those of
origin. CICs are believed to be responsible for tumor initiation,
progression, and resistance to therapeutic agents (4–6); therefore,
treatments aimed at blocking/destroying CICs should be pursued.
Despite the advent of new diagnostic tools and targeted molecule
agents, most CRC patients die of metastatic disease and almost half
of patients receive chemotherapy without clinical benefit. Along
this line, immunotherapy based on antitumor-specific T cells may
represent a promising treatment, as it may induce the killing of
CICs that remain after surgery and that are resistant to standard
therapies.
The majority of immunotherapy protocols carried out in CRC
patients are based on vaccination with defined Ags loaded or not on
dendritic cells that, despite early promising results, has led to limited
clinical benefit (7). Thus an improvement in this strategy is urgently
needed. A possible explanation for these limited clinical results may
lie in the failure to target CICs, a hypothesis corroborated by the
evidence that an increase in “stemness” profile was obtained in
postvaccinated glioblastoma patients and following antitumor T cell
activity (8, 9). We have previously characterized the immune profile
of CICs isolated from glioblastoma multiforme (GBM) tissues and
found low immunogenicity (10). Moreover, a preferential induction
in vitro of Th2-type responses occurred following the coculture of
CICs with autologous PBMCs (10). Cancer-testis Ags have been
found to be expressed by mesenchymal stem cells and to regulate
the epithelial-to-mesenchymal transition, a process involved in de-
velopment of metastases; thus these Ags may possibly have a role in
the stemness properties of cancer cells and could represent target
molecules for immunotherapy (11). Nevertheless, antitumor im-
munity could be attenuated by tumor-related immunosuppressive
mechanisms that have been described in association with CICs
isolated from melanoma or GBM (12–14). These findings suggest
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that a detailed immunological characterization of CICs isolated
from different human tumors is a relevant issue to design new CIC-
targeted immunotherapeutic interventions. Of interest, we found
that the CRC self Ag COA-1, encoded by the UBXD5 gene, was
expressed at high levels by both CICs and FBS tumor cells. The
peculiarity of this Ag is that it is recognized by T cells preferentially
on tumor cells and not on normal cells, suggesting that a differential
processing of this Ag can occur in these cells (15, 16). Although
biological characterization of this Ag still needs to be accom-
plished, our group demonstrated that COA-1 can elicit specific
T cell responses in cancer patients and not in healthy donors (16).
Indeed, among different tumor Ags tested, COA-1 was found to




Tumor samples and PBMCs were obtained from patients with a diagnosis of
primary CRC admitted for surgery at the San Raffaele Hospital, Milan, Italy.
The clinical characteristics of these patients are reported in Supplemental
Table I. The Institutional Review Board and the Ethics Committee of the
San Raffaele Hospital approved this study and an informed consent was
obtained from the participating subjects.
The MHC class I and class II typing of the patients was performed on
their PBMCs by single-stranded oligonucleotide probe–PCR typing (10).
CICs were isolated in vitro by the mechanical processing of primary
tumor tissues (#1076, 1247, 111011, and 14583) and were cultured in the
form of spheres (colon-spheres) in the presence of stem cell–permissive
medium (DMEM/F12) containing 20 ng/ml epidermal growth factor and
50 ng/ml fibroblast growth factor 2 (PeproTech, Rocky Hill, NJ), as pre-
viously described (17). Part of the primary cell dissociation of CRC
tissues was cultured in the presence of RPMI 1640 supplemented with
10% FBS (Biowittaker, Lonza, Treviglio, Italy), hereafter denominated
FBS tumor cells (#1076, 1247, 111011, 1039, and 20299), and repre-
senting the differentiated tumor cell counterparts, as previously described
(10, 17, 18); these cell lines were used in parallel with CICs. Additional
CIC lines (#1, 2, and 3) isolated from primary CRC patients have been
previously characterized (19). Other cell lines used in this study were as
follows: the CRC 1869 col, 1872 col (15), and SW480 (American Type
Culture Collection); and the 1869 B cells immortalized with EBV (1869
EBV-B) (15). These cell lines were cultured in vitro with RPMI 1640 plus
10% FBS.
Monoclonal Abs used for immunofluorescence analysis
The expression of CIC- or CRC-associated markers has been evaluated by
immunofluorescence (IF) and cytofluorimetric analysis using the following
Abs: anti-EpCAM VU-1D9 (Santa Cruz Biotechnology, Santa Cruz, CA);
anti-HCAMMEM-85 (Santa Cruz Biotechnology); anti-CD24 SN3 (Novus
Biological, Littleton, CO) or 528807 (R&D Systems, Minneapolis, MN);
anti-Myc 3C118 (Santa Cruz Biotechnology); anti-CD133 293C3 (Milte-
nyi Biotec, Bergisch Gladbach, Germany); anti-CEA Col1 (Santa Cruz
Biotechnology); anti-SOX2 245610 (R&D Systems); anti-S100A4 1F12-
1G7, anti-S100A6 6D1 (Abnova, Taipei City, Taiwan); anti-Oct-3/4 40/
Oct3 (Becton Dickinson Pharmingen, Palo Alto, CA); anti-Nanog M55-
312 (BD Pharmingen) and anti-Lgr5 4D11F8 (BD Pharmingen).
MHC class I and class II HLA expression by CIC and FBS tumor cell lines
was determined by IF and flow cytometry analysis using the mAbs W6/32
and L243 (BD, Pharmingen), respectively. The expression of Ag-processing
machinery (APM) and MICA, MICB, and ULBPs molecules by these cell
lines was determined using the previously described purified Abs provided by
one of us (S.F.) and by Amgen (Thousand Oaks, CA), respectively (10). The
expression of immunoregulatory molecules or cytokines and their receptors
was assessed using the following Abs: anti–IL-4 3007 and anti–IL-4R
25463 (R&D Systems). Furthermore, tumor-associated Ag (TAA) expres-
sion by both CICs and FBS tumor cells was determined by the use of anti–
NY-ESO-1 E978 (Zymed Laboratories, San Francisco, CA), anti–IL-13R (2
B-D13; Santa Cruz Biotechnology) mAbs, and anti-MAGE 57B and 6C1
kindly provided by Dr. G. Spagnoli (Institute of Surgical Research and
Hospital Management, Department of Biomedicine, University Hospital of
Basel, Basel, Switzerland). The PE-conjugated goat anti-mouse IgGs (DAKO,
Glostrup, Denmark) were used for fluorochrome staining of the Abs used. The
flow cytometry analysis was performed by the FACSCanto HTS instrument
(Becton Dickinson).
The ALDEFLUOR staining kit (STEMCELL Technologies, Vancouver,
BC, Canada) was used for aldehyde dehydrogenase (ALDH-1) detection;
briefly, the fluorescent aldefluor reagent, which is a substrate for ALDH-1, is
used for staining of cells and diffuses into cells. The amount of fluorescent
ALDH-1 reaction product accumulated in the cells directly correlates to the
ALDH-1 activity and was determined by standard cytofluorimetric analysis.
The phenotype characterization of T cell lines was carried out bymulticolor
IF and cytofluorimetric analysis (LSR II Fortessa; BD) with fluorochrome-
conjugated anti-CD3, -CD4, -CD8, CD16, -CD56, -CD57, -CD28, -CD27,
-CD45RA, -CD45RO, -CCR7, -CD25, -CD127, -CD134, -CD137 (BD,
Pharmingen), and –NKG2D 1D11 (eBioscience, San Diego, CA) mAbs.
Results are expressed as mean ratio of fluorescence intensity (MRFI), rep-
resenting the ratio between the mean fluorescence intensity of cells stained
with the selected mAb and that of cells stained with the negative Ab control
(10) or, for the multiparametric lymphocyte phenotype analysis, as percent-
age of positive cells.
In vitro differentiation assay
CICs cultured in vitro as serum-free–derived spheres, following mechanical
dissociation of the spheres to single cells by extensive pipetting (17), were
plated in six-well culture plates in the presence of DMEM plus 5% of FBS,
representing the differentiating agent, as previously described by Vermeulen
and coworkers (20) for 7–10 d to induce the cells to acquire the adherence-
dependent growth and the differentiated phenotype.
Confocal microscopy analysis
CRC-derived CICs and FBS tumor cells were cultured (3–53 104 cells per
well) onto cover glasses precoated with Matrigel in 24-well plates in
culture medium. Cells were fixed onto glass either with methanol for 10
min at –20˚C or with 4% paraformaldehyde for 20 min at room temper-
ature, washed with PBS, and then treated with PBS plus 0.1% Triton for 10
min. Afterward, cells were incubated for 30 min at 25˚C with the following
primary Abs: anti-Survivin 8E2 (Thermo Scientific, Fremont, CA); anti-
MAGE 57B and 6C1, kindly provided by Dr. G. Spagnoli (Institute of
Surgical Research and Hospital Management, Department of Biomedicine,
University Hospital of Basel, Switzerland); and anti–COA-1 polyclonal Ab
(ProteinExpert, Grenoble, France). The bound Abs were visualized with
goat anti-mouse IgG Alexa Fluor 594 (Molecular Probes, Eugene, OR) or
the Alexa Fluor 488–conjugated goat anti-mouse IgG F(ab9)2 fragment
(Molecular Probes). Glasses were extensively rinsed with PBS and then
mounted on microscope slides with VECTASHIELD antifade medium
containing DAPI (Vector Laboratories, Burlingame, CA). Confocal laser-
scanning microscopy (Leica Microsystems, Milan, Italy) analysis was then
carried out. Multiple cells were analyzed for each staining condition, with
320, 360, and 3100 magnifications.
In vivo tumorigenicity
Tumorigenicity of CICs was determined by s.c. transplantation of cells into
adult (8-wk-old) NOD/SCID CB-17 mice (Charles River Laboratories,
Calco, Italy). Micewere maintained according to the animal care committee
guidelines of the San Raffaele Foundation Centre. A total of 13 105 cells of
either CICs or FBS tumor cells suspended in 100 ml physiological solution
mixed at 1:1 ratio with Matrigel-containing medium (DMEM with 1%
penicillin/streptomycin) were injected s.c. into the flank of NOD/SCID
CB-17 mice. Mice were monitored every 3 d, and tumor formation was
determined by caliper measurement. After 3–6 wk, visible tumors arose
and their volumes (V) were determined using the following formula: V =
(a 3 b2)/2, with a = length and b = width. When the tumor size reached
1.5–2 cm3, the mice were sacrificed and tumor tissues were processed
either for morphological and immunohistochemical analysis or for in
vitro culture.
For serial dilution experiments, 1 3 105, 1 3 104, 1 3 103, or 1 3 102
cells of either CICs or FBS tumor cell suspensions were injected into
NOD/SCID CB-17 mice, as described above.
Xenograft tissues obtained by the injection of 1 3 105 cells of either
CICs or FBS tumor cells were mechanically processed and the cell sus-
pensions cultured in vitro with the permissive CIC growth medium or
RPMI 1640 plus 10% FBS, respectively. Then, serial cell transplantations
were performed by injecting 1 3 105 cells into secondary NOD/SCID
CB-17 mice. Tumor volumes were monitored weekly and compared
with those of the first cell transplantation. Three mice for each group were
used for the in vivo tumorigenic assays, and each experiment was repeated
three times.
Statistical analysis of differences between tumor volumes was performed
using the two-tailed t test (p , 0.05).
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Detection of cytokine and soluble factors released by CRC
cells
CRC CICs and FBS tumor cell lines (23 105/ml) were cultured in DMEM
(Biowittaker, Lonza, Basel, Switzerland), without growth factors or FBS,
for 48 h at 37˚C; then supernatants were collected, centrifuged at 3000 rpm
for 15 min, and stored at 280˚C. TGFb-1 and TGFb-2 released by CRC
cells were detected by ELISA (DRG Instruments, Marburg, Germany).
PGE2 detection in these supernatants was performed using the specific EIA
Kit (Cayman Chemical, Ann Arbor, MI). Moreover, IL-4, IL-5, IL-6, IL-8,
IL-10, IL-13, and TNF-a were determined in the supernatants by
SearchLight Array Technology (Thermo Fisher Scientific Pierce Protein,
Rockford, IL). Data were represented as picograms per milliliter, and the
significance of the differences of soluble factor release by CRC cell lines
was determined by the two-tailed t test (p , 0.05).
Cell division analysis by CFSE staining
PBMCs (1 3 106 cells) isolated from CRC patients or from healthy donors
were labeled with 1 mM CFSE (Molecular Probes, Invitrogen) for 8 min at
37˚C. The labeled cells were stimulated with 10 mg/ml PHA plus Con A
(Sigma-Aldrich, Milan, Italy) in the presence or absence of irradiated (300
Gy) autologous CICs or FBS tumor cells with either anti–IL-4 or anti–
IL-4R mAbs or their combination. The homeostatic cytokine recombi-
nant human (rh) IL-7 (5 ng/ml) (PeproTech) was added to all different
cultures. Mixed lymphocyte tumor cell (MLTC)–derived T cells were
also assessed for cell division after coculture or not with autologous
CICs or FBS tumor cells and in the presence or not of anti–IL-4 or –IL-
4R mAb. After 72 h of stimulation, cells were stained with CD3-Pacific
Blue (Becton Dickinson) and were acquired with the LSR II Fortessa
cytofluorimeter (Becton Dickinson); data for CD3+ gated cells were
analyzed with FCS Express 4 software (De Novo Software, Los
Angeles, CA).
For the Transwell experiments, 24-well Transwell plates with a 0.4-mm
pore membrane (Costar, Corning, NY) were used to separate the PBMCs
from the CRC CICs. PBMCs stained with CFSE were plated with PHA/
Con A into the lower chamber at 13 106 cells per well, and CICs (13 105
cells per well) were cultured in the upper chamber of the Transwell insert
in the presence or not of anti–IL-4 mAb. After 3 d of coculture, the PBMCs
were analyzed for proliferation, using flow cytometry as described above.
CFSE-stained PBMCs, with or without PHA/Con A, were used as positive
or negative controls, respectively. Data represent the mean of the prolif-
eration index, that is, the total number of divisions divided by the number
of cells that went into division, for each tumor cell line from three inde-
pendent experiments or, where indicated, the percentage of divided cells.
The efficiency of the neutralization of IL-4 and IL-4R by mAbs has been
determined by evaluating the proliferation rate of PBMCs cultured in vitro
for 5 d in the presence of 100 IU IL-2 and 10 ng/ml IL-4 (PeproTech)
(Table II). Then PBMCs were washed, and a 3-d CFSE staining assay was
performed as described above.
Isolation of CRC-reactive T lymphocytes
PBMCs from the peripheral blood of CRC patients (#1076, 1247, and
14583) were cultured in vitro in the presence of autologous irradiated (300
Gy) colorectal CICs or, when available, FBS tumor cells, pretreated or not
with rhIFN-g (1000 IU/ml; PeproTech), with 100 IU/ml rhIL-2 (Chiron
Corporation, Emeryville, CA) and 10 ng/ml rhIL-7 (PeproTech) in X-
VIVO-15 (Cambrex, Lonza, Basel, Switzerland) plus 5% human serum.
Moreover, in some of these cultures 10 mg/ml of either the neutralizing
anti–IL-4 3007 mAb or the anti-IL-4R 25463 mAbs (R&D Systems) was
added simultaneously with the stimulating tumor cells. Cell cultures were
restimulated weekly with irradiated autologous CICs or FBS tumor cells in
the presence or not of anti–IL-4 or anti–IL-4R mAbs; starting from the
third week of culture, the reactivity of the T lymphocytes against colorectal
CIC or FBS tumor cell lines was determined by IFN-ɣ secretion, measured
by ELISPOT assay as previously described (10). The T cells (1–4 3 104
cells per well) were incubated in flat-bottom 96-well plates in the presence
of 1.7 3 104 cells per well of CRC cell lines or K562 or EBV-B cells.
The specificity of T lymphocyte recognition was assessed by inhibition
of cytokine release after preincubation of the target cells with 10 mg/ml
each of the anti-HLA class I mAb W6/32 and the anti-HLA class II (DR)
mAb L243. T lymphocytes incubated with mitogens, such as Con A or
PHA, were the positive controls. Unstimulated T lymphocytes repre-
sented the negative control. Results represent averages of triplicates with
SD # 10%; statistical analysis of differences between means for cyto-
kine release assays was performed using the two-tailed t test (p , 0.05).
These experiments have been repeated three times, showing consistency
of results.
Results
Isolation and biological characterization of CICs from CRC
tissues
Spheroid cell cultures, known to be enriched for CICs (1–3), were
isolated and propagated in vitro by sphere-forming assay from
seven primary CRC surgical specimens (10, 19). In three of seven
cases, adherent growing tumor cells were also established in the
presence of FBS (FBS tumor cells). This allowed us to isolate two
major subpopulations of tumor cells: those with cancer-initiating/
stemness properties (Supplemental Fig. 1A) and the bulk of dif-
ferentiated tumor counterparts (Supplemental Fig. 1C), as previ-
ously described by a few groups, including ours, in the GBM model
(10, 18, 20).
Initially, by analyzing the expression of Nanog, OCT-4, Sox2,
ALDH-1/Aldefluor, CD133, CD44, CD24, Ep-CAM and CEA, we
determined that the phenotype of these spheroid cell lines was
concordant with that previously described for CRC-derived CICs
(1–3, 21–23), as shown by the representative results of the #1076
CICs and FBS tumor cell pairs (Supplemental Fig. 2A). Indeed,
we demonstrated that CRC-derived CIC-associated markers, such
as CD44, CD24, EpCAM, and CEA, were significantly (t test p ,
0.01) upregulated in all CICs versus FBS tumor cells (Supple-
mental Fig. 2A). By cell sorting we could select from both CICs
and FBS tumors the cell subpopulations with different levels, al-
though the range percentage of positive cells was 82–99% of
MRFI of ALDH-1 expression (representative data of #1076 cell
lines are shown in Supplemental Fig. 2B). ALDH-1-high and
ALDH-1-low cell populations were isolated from CICs (MRFI = 12
and 7, respectively; Supplemental Fig. 2B), whereas from FBS tu-
mor cells only ALDH-1–low and ALDH-1-negative cells (MRFI =
3.7 and 1, Fig. 1B) could be obtained. Moreover, high levels of
CD24, CD44, CD133, Ep-CAM, and CEA were found in associ-
ation with ALDH-1 expression (Supplemental Fig. 2B). Thus, we
confirmed that ALDH-1 expression is upregulated and correlated
with the expression of CIC-associated markers in our spheroid cell
cultures compared with FBS tumor cells. Moreover, the sphere-
forming cells homogeneously expressed (85–98% of positive
cells; MRFI: 5–9; representative results from #1076 and 1247 are
shown in Supplemental Fig. 1D, 1E) the colon stem cell–specific
marker Lgr5 (24), whereas FBS tumor cells showed weak or neg-
ative expression, with 11–13% of positive cells that did not show
statistically significant differences in the mean fluorescence inten-
sity (MRFI = 1.4–1.6), compared with the negative control (Sup-
plemental Fig. 1F, 1G). Thus the results of MRFI showed a clear
overexpression of Lgr5 by CICs compared with FBS tumor cells.
In addition, the sphere-forming cells displayed differentiation
ability following the culture in vitro for 7 d in the presence of FBS.
These cells lost the ability for growth in suspension (see Supple-
mental Fig. 1A) and acquired the single-cell adherence–dependent
growth (Supplemental Fig. 1B), similarly to the FBS tumor cells
(Supplemental Fig. 1C).
The tumorigenic ability of these spheroid cell cultures and of their
FBS tumor cell pairs was assessed by s.c. transplantation of different
numbers of cells (1 3 105, 1 3 104, 1 3 103, 1 3 102, and 1 3 10
cells) in immunodeficient NOD/SCID CB-17 mice and by the
weekly monitoring of tumor formation. Fig. 1A and 1B shows
representative results from patient #1076. Notably, cells obtained
from spheroid cell cultures formed tumor nodules more efficiently
than did FBS cells (Fig. 1A versus 1B; p , 0.05). In fact, spheroid
cells showed detectable tumors from day +17, reaching 1.87, 1.2,
and 0.87 cm3 of volume following injections of 1 3 105, 1 3 104,
and 1 3 103 cells, respectively (Fig. 1A). Of note, tumor formation
was obtained also following injections of 1 3 102 CICs (Fig. 1A),
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whereas FBS tumor cells generated tumors with small dimensions
(0.9 and 0.4 cm3) after transplantation of 13 105, 13 104 cells and
failed to generate tumors after injection of 1 3 103 or 1 3 102 cells
(Fig. 1B). Of mice injected with 100 cells of CICs, 78% developed
tumors, whereas the same number of FBS cells induced tumors in
only 22% of tumor-bearing mice (Fig. 1D). Of note, 33% of mice
developed detectable tumors after inoculation of 10 CICs but not of
10 FBS cells (Fig. 1 D). The morphological characterization of
CRC tissues derived from surgical specimens and from xenografts,
studied by H&E staining, revealed that the sphere-forming cells
following transplantation in mice can more efficiently give rise to
neoplastic tissues that resemble the primary tumors of origin,
compared with the FBS tumor cells (representative results are
shown in Supplemental Fig. 1H–M). Moreover, serial transplanta-
tion into immunodeficient mice showed that efficiency in tumor
formation by CICs was similar between the first inoculation and the
second round of injection of xenograft-derived cells. On the con-
trary, half of tumor size was recovered following the second round
of in vivo injection of FBS tumor cells (Fig. 1C). Therefore, on the
basis of available tools to isolate and define CICs, it appears that our
sphere-forming cells indeed constitute a homogeneous cell pop-
ulation that displays CIC properties. FBS tumor cells showed
phenotypical and functional characteristics distinct from those of
CICs, but we cannot exclude that a rare subpopulation of cells with
CIC properties could still be present in these cell lines (11–13% of
Lgr5low-expressing cells) or that these cells can have high grade of
plasticity and thus modulate their functional state.
Taken together, these results indicate that the sphere-forming
cells isolated in vitro from CRC tissues displayed the pheno-
typic characteristics and high tumorigenicity that resemble these
features in CICs, and therefore they can represent bona fide CICs.
Immunological profile of CRC-derived CICs versus FBS tumor
cells
The immunological profile of CICs compared with their non-CIC
counterparts was determined by IF and cytofluorimetric analysis by
evaluating the expression of MHC class I and II; NKG2D ligands;
and, at the intracellular level, an array of molecules belonging to the
APM, including MHC class I molecules and their heavy chains
(e.g., HLA-HC), b2-microglobulin, constitutive proteasome subunits
(D, MB1, and Z), immunoproteasome (LMP2, 7, and 10), trans-
porter molecules (TAPs), and chaperon molecules (tapasin, calnexin,
calreticulin, and ERp57). Of interest, a frequent downmodulation of
MHC class I was found in CICs, compared with their autologous
FBS tumor cells, whereas a failure in the expression of MHC class II
molecules was evident in both CICs and FBS tumor cells (Supple-
mental Fig. 2C). All the APM molecules were downmodulated or
absent in CICs compared with the FBS tumor cells (representative
FIGURE 1. Characterization of CIC properties in CRC sphere-forming cell cultures. The tumorigenic properties of CICs compared with autologous FBS
tumor cells (A, B) were evaluated by the s.c. injection of 1 3 105, 1 3 104, 1 3 103, 1 3 102, and 10 cells into immunodeficient NOD/SCID CB17 mice
(see Materials and Methods). Data are indicated as the means 6 SD of tumor volumes deriving from three independent experiments. Three mice per
treatment were used for each experiment. *p , 0.05, **p , 0.01 (99% t test). (C) Either CICs or FBS tumor cells (1 3 105 cells) were mixed at a 1:1 ratio
in Matrigel-containing medium (DMEM with 1% penicillin/streptomycin; 100 ml of final volume) and transplanted into immunodeficient NOD/SCID CB17
mice. Tumor formation was monitored weekly, and when tumor sizes reached 1.5 cm3 the mice were sacrificed and tumor tissues were removed and
mechanically processed to isolate single cells. These cells, derived from either CICs or FBS xenograft tumors, were cultured in vitro and subsequently
transplanted into secondary mice and tumor formation was monitored weekly as well. (D) The table indicates the number of mice who developed tumors
following the injection of either CICs or FBS tumor cells (patient #1076); the results are from the use of three mice for each condition for three experiments
(no. of mice per condition = 9).
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results of some APM molecules from patients #1247, 1076, and
111011 are shown in Supplemental Fig. 2D), whereas NKG2D
ligands were expressed commonly in all the CRC cell lines and
with upregulation, although to a variable extent in CICs compared
with their FBS tumor cell pairs (Supplemental Fig. 2C). In addi-
tion, no or low upregulation of these molecules was observed by
treatment with IFN-a or -g (data not shown). These results suggest
that a low efficiency or impairment of Ag processing and presen-
tation can occur preferentially in association with CICs.
In addition, we found that IL-4 was detectable at the membrane
level in all the CICs (seven of seven cell lines with 66–82% of
positive cells) and was overexpressed (p , 0.01) in these cells
compared with their FBS pairs, although autologous FBS tumor
cells were available for only three patients (Fig. 2A). This cyto-
kine was commonly found in the cytoplasm of both types of tumor
cell lines. We have then analyzed three additional FBS tumor cells
available in our laboratories (#1039, 20299, and 1869), confirming
the previously obtained results (Fig. 2A). IL-4R was detected in
six of seven CICs both at the membrane and, with higher levels, in
the cytoplasm, whereas it was almost negative in FBS tumor cells
(Fig. 2 A). The secretion of IL-4 was found to be preferentially
associated with CRC-derived CICs, with low or negative secretion
by FBS tumor cells (#1076 and 1247, respectively; Fig. 2B). In
addition, the pretreatment of cells with IFN-g increased the levels
of cytokine release, with statistically significant differences (p ,
0.005) between CICs and their FBS tumor cell counterparts (Fig.
2B). These results suggest that, as previously documented (19,
25), IL-4 and IL-4R, both membrane associated and as soluble
factors, are preferentially expressed by CICs isolated from CRC
and correlated with their low immunogenic profile.
The neutralization of CIC-associated IL-4 can rescue the
proliferative activity of T lymphocytes
To determine the role of CIC-associated IL-4 on T cell–mediated
immune responses, these cells were cocultured with autologous
(#1076, 1247, and 14583 CRC patients) or with allogeneic healthy
donors (patients #1, 2, and 3) PBMCs for 72 h with PHA/Con A.
These cocultures were set up with or without neutralizing Abs
directed to IL-4 or IL-4R or both. As negative control, FBS tumor
cells (#1076 and 1247) were used as stimulators. The proliferative
activity of CD3+ T cells was determined by CSFE staining and
FACS analysis. As shown in Fig. 3, the efficiency of proliferation
(indicated as proliferation index) of T cells was reduced (1.5–2.6
times, p , 0.001) by culture with CICs, compared with stimula-
tion with mitogens alone (PHA and Con A). Of interest, recovery
of T cell proliferation was obtained when IL-4–specific mAbs
were present in the cocultures, achieving values for the prolifer-
ation index similar to those of the positive controls (PHA/Con A)
for all the six CICs isolated from CRC patients (Fig. 3). Of note,
the coculture of PBMCs with autologous CICs preincubated with
anti-IL-4R mAb (#1076, 1247, 14583, 1, 2, and 3) did not affect
the T cell proliferation (Fig. 3). Moreover, the pretreatment of
CICs with the combination of anti–IL-4 and –IL-4R mAbs con-
firmed that the blocking of IL-4 is sufficient to lead to the rescue
of T cell proliferation. These data indicate that CIC-associated
IL-4 is responsible for the CIC-mediated inhibition of T lympho-
cyte proliferation, possibly by direct interaction with the IL-4R
expressed on T cells and not by the activation of an autocrine
pathway on CICs.
No inhibition of T cell proliferation by coculture, in the presence
or not of anti–IL-4 mAb, with autologous FBS tumor cells (#1076
and 1247; Fig. 3) was detected. Representative CFSE staining
histograms from patient #1247 are represented in Supplemental
Fig. 3. Of interest, we found that cell-to-cell contact was necessary
for CICs to mediate the negative immunomodulatory activity on
T cells. T cells from CRC patients were cultured with CRC-
derived CICs in Transwell plates, thus preventing direct contact
between the two types of cells. We found that T cell proliferation
was not affected by CICs, compared with the positive control
(representative results from patients #1247 and 1076 are shown
in Table I). T cell proliferation was partially inhibited by cocul-
turing T lymphocytes in Transwell plates with CICs pretreated
FIGURE 2. Expression or secretion of IL-4 and IL-4R by CICs and FBS tumor cell lines isolated from CRC patients. (A) IL-4 and IL-4R expression on
CICs and FBS tumor cells [#1076, 1247, 111011, 14583, 1, 2, 3, 1039, 20299 and 1869 (A)] was evaluated by membrane or intracellular IF. For the mAbs
used, see Materials and Methods. Data are represented as MRFI; significant values are MRFI $ 2. The results are the mean of three independent
experiments (SD , 5). (B) Evaluation of soluble IL-4 in cell culture supernatants of CRC CICs or FBS tumor cells pretreated or not with IFN-g (1000 IU/
ml for 48 h) was performed by SearchLight Array Technology (see Materials and Methods). The data are expressed as picograms per milliliter. Results
represent averages of duplicates with SD # 10%. *p , 0.5, **p , 0.05, ***p , 0.001.
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with IFN-g, thus upregulating the secretion of IL-4 (Fig. 2B), and
indeed the blocking of the secreted IL-4 by the specific mAb could
restore the efficiency of T cell proliferation (Table I). This finding
indicates that the IFN-g–induced secretion of IL-4 by CICs can
play a partial role in inhibiting T cell proliferation, whereas most of
the immunomodulatory activity by CICs is due to the membrane-
associated cytokine and, thus, to cell-to-cell contact between CICs
and T lymphocytes. In addition, the evidence that Transwell co-
culture with CICs in the presence or not of IL-4 blocking did not
affect T cell proliferation indicates that this phenomenon is not
dependent on the possibly reduced viability of CICs following
treatment with anti–IL-4 mAb.
These results demonstrate that IL-4, which is expressed at high
levels by CRCCICs, is one keymediator in the immunomodulatory
activity of these cells. In addition, we showed that this CIC-associated
inhibitory role is mainly dependent on cell-to-cell contact with
T cells.
The blocking of CIC-associated IL-4 augments the efficiency of
anti-CRC Th1-type tumor-specific reactivity in autologous
settings
PBMCs from CRC patients (#1076, 1247, and 14583) were stim-
ulated in vitro with autologous irradiated CICs or, when available
(#1076 and 1247), with FBS tumor cells (MLTC culture). The
pattern of reactivity of T cells deriving from these MLTCs against
autologous tumor cell lines was determined by IFN-g release assay
(ELISPOT). As shown in Fig. 4, tumor-reactive T cells could be
isolated from PBMCs stimulated in vitro with autologous CICs (Fig.
4A–C) from patients #1247, 14,583, and 1076, respectively. The
reactivity of these T cells against CICs was HLA class I restricted
(50–52% of reduction of cytokine secretion, in the presence of the
anti-HLA class I mAb W6/32, p , 0.05) for two of three patients
(#1247 and 1076; Fig. 4A, 4C), whereas 50% of reduction (p ,
0.05) of IFN-g release after stimulation with CICs was achieved
with anti-HLA class II mAb (L243) only for patient 1076 (Fig. 4C).
MLTCs stimulated in vitro with autologous CICs showed higher
reactivity against FBS tumor cells, when used as target (Fig. 4A,
4C), although all tumor cells to be used as target cells were pre-
treated with IFN-g to optimize the Ag processing and presentation.
These findings were in line with the low immunogenicity of CICs
and with the reduced activity of IFN-g treatment in upregulating
APM in these cells compared with FBS tumor cells (as discussed
previously). The stimulation of lymphocytes with PHA and Con A
represented the positive controls of the assays.
The phenotype of the CIC-stimulated, MLTC-derived T cells
resulted in a preferential selection of CD4+ T cells (73% of pos-
itive cells; data not shown) and a lower frequency of CD8+ T cells
(27% of positive cells; data not shown). On the contrary, the
FIGURE 3. Restoration of T cell proliferation in vitro by blocking CIC-
associated IL-4. PBMCs (1 3 107) from CRC patients (patients #1076,
1247, and 14583) or healthy donors (for patients #1, 2, and 3) were stained
with 1 mM CSFE and stimulated with PHA/Con A in the presence or not of
3-d cultured CICs or FBS tumor cell lines. The coculture of tumor cells
and autologous or allogeneic PBMCs was performed in the presence or not
of anti–IL-4 mAb, anti–IL-4R mAb, or both the mAbs. Then, cells were
harvested and the CFSE profile was assessed by flow cytometry. Data are
referred to CD3+ gated cells. Data represent the proliferation index that is
the total number of divisions divided by the number of cells that went into
division. Data represent the mean of the proliferation index for each tumor
cell line from three independent experiments. **p , 0.05, ***p , 0.001.
Table I. The CIC-associated inhibition of T cell proliferation is dependent on cell-to-cell contact
Patient Mitogen Tumor Cells in Transwell Plate % Divided Cellsa Proliferation Indexb
1076 No No 0.34 1.20
PHA/Con A No 69.20 2.93
PHA/Con A CICs 60.38 3.20
PHA/Con A CICs + anti–IL-4 63.11 2.82
PHA/Con A CICs + IFN-g 42.60 1.80
PHA/Con A CICs + IFN-g + anti–IL-4 58.40 2.30
1247 No No 0.45 1.14
PHA/Con A No 70.20 2.84
PHA/Con A CICs 73.96 2.66
PHA/Con A CICs + anti–IL-4 70.01 2.70
PHA/Con A CICs + IFN-g 37.26 1.47
PHA/Con A CICs + IFN-g + anti–IL-4 65.20 2.70
PBMCs from CRC patients were stained with 1 mM CSFE and plated with PHA/Con A in the bottom of Transwell plates. In
the 0.8-mm membrane insert well, CICs pretreated or not for 48 h with 1000 IU/ml of IFN-g, with or without anti–IL-4 mAb,
were cultured. After 3 d, T cells were harvested and the CFSE profile was assessed by flow cytometry. Data refer to CD3+ gated
cells.
aThe % Divided Cells is the percentage of cells of the original sample that divided.
bThe Proliferation Index is the total number of divisions divided by the number of cells that went into division. Bold data
represent the percent of divided cells or the proliferation index of the positive controls or of rescued values following the
neutralization of IL-4.
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phenotype analysis of MLTC-derived T cells stimulated with FBS
cells revealed an enrichment (75% of positive cells) of CD3+CD8+
CD45RO+ T cells and a minor population (25% of positive cells)
of CD3+CD4+CD45RO+ T lymphocytes (data not shown). More-
over, the phenotype characterization of the #1247 MLTC with
CICs showed 26% of CD3+CD8+CD45RO+, 40% of CD3+CD4+
CD45RO+ T cells, and 34% of CD16+CD56+CD57+CCR7- NK
cells (data not shown). Of note, no and low levels of Il-4 and IL-5
release, respectively, were detected by these T cells after stimu-
lation with tumor cell lines (data not shown).
We have then set up MLTCs with autologous CICs in the presence
of the neutralizing anti–IL-4 mAb, and as represented in Fig. 4A–C,
the pattern of tumor reactivity of these cells showed an augmen-
tation (1.7–1.9 times increase) of CIC recognition, compared with
the recognition of these cells by MLTCs without the blocking of
IL-4. This reactivity was specifically inhibited by W6/32 mAb (Fig.
4A–C), whereas their recognition of autologous FBS tumor cells
was not affected (Fig. 4C) or even slightly reduced (Fig. 4A) by the
anti–IL-4 mAb. The phenotype characterization of the MLTCs with
the anti–IL-4 mAb showed an enrichment of CD3+CD8+CD45RO+
(90%), whereas for patient #1247 NK cells were no longer de-
tectable (data not shown). The neutralization of IL-4 can affect the
pattern of reactivity of MLTC possibly by modifying the frequency
and/or the avidity of Ag-specific T cells. This may lead to the in-
crease of specific reactivity against CICs (Fig. 4A–C) and either to
the reduction of recognition of FBS tumor cells (Fig. 4A) or to the
decrease of this specific reactivity (decrease of the inhibition of FBS
tumor cell reactivity by blocking with MHC class I mAb) (Fig. 4C).
MLTCs stimulated in vitro with autologous FBS tumor cells
recognized specifically (inhibition of IFN-g release by W6/32 and/
or L343 mAbs) the autologous tumor cells, with higher cytokine
release when FBS tumor cells were used as target cells, compared
with CICs (Fig. 4A, 4C). Moreover, no modification of the pattern
of reactivity was observed by adding the anti–IL-4 mAb to these
MLTCs (data not shown), in line with the low expression and
secretion of IL-4 by 1076 or 1247 FBS tumor cells (Fig. 2A, 2B).
In addition, the phenotype of this MLTC comprised 60% of CD3+
CD4+CD45RO+ and 37% of CD3+CD8+CD45RO+, whereas no
NK cells were detected (data not shown).
The proliferative ability of MLTCs from patients 1076, 1247, and
14583 were also assessed by CFSE staining and cytofluorimetric
analysis. The results, reported in Table II, confirmed that the 72-h
incubation of MLTC-derived cells with autologous CICs reduced
the proliferation of these T cells. A recovery of the rate of prolif-
eration was achieved when these T cells were cultured with anti–IL-
4 mAb (Table II). Furthermore, the supply of the anti–IL-4 mAb to
FIGURE 4. Specific tumor reactivity of T cells from MLTCs of CRC patients. PBMCs isolated from CRC patients 1076, 1247, and 14583 were
stimulated in vitro in the presence or not of the neutralizing IL-4 mAb with autologous irradiated CICs (A–C) or, when available, FBS tumor cells (A, C).
Following 3 wk of culture, the reactivity against autologous tumor cell lines was assessed by IFN-g release (ELISPOT assay). Data are expressed as no. of
spots per 5 3 104 cells and are subtracted from the background of IFN-g release of T cells alone. (D) The reactivity of CIC- or FBS-stimulated MLTCs
against allogeneic HLA-matched EBV-B cells (1869) pulsed with the HLA-A24 epitope (SLQDLSELV, Ref. 16) or T2 cells loaded with the HLA-A2–
restricted epitope (FMTRKLWDL, Ref. 16) from COA-1. The positive controls of T cell stimulation are PHA/Con A. Data are expressed as no. of spots per
5 3 104 cells and subtracted from the background of IFN-g release by T cells alone or stimulated with allogeneic target cells. Results represent averages of
triplicates with SD # 10%; statistical analysis of differences between means of IFN-g released by T cells was performed by two-tailed t test. Each ex-
periment has been repeated three times, showing consistency of the results.
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the MLTCs concomitantly with tumor cell stimulation led to higher
levels of restoration of T cell proliferation. The proliferative rate of
MLTCs stimulated with FBS tumor cells was not affected either by
these cells or by the blocking of IL-4 signaling (data not shown);
these results were similar to those obtained for fresh PBMC pro-
liferation (Fig. 3).
Taken together, these data indicate that T cell responses against
CICs can be obtained from the peripheral blood of CRC patients,
although with lower efficiency, compared with FBS tumor cells. Of
interest, the neutralization of IL-4 along with the stimulation of
T cells with autologous CICs can lead to the augmentation of both
antitumor Th1 responses and T cell proliferation.
COA-1 recognition by MLTC–derived lymphocytes stimulated
with autologous CICs
The reactivity of T cells from MLTCs of three CRC patients
(#1076, 1247, and 14583) stimulated in vitro with autologous
CICs has been assessed against a panel of TAAs (SVV-1, NY-
ESO-1, IL13Ra2, Ep-CAM, and COA-1) (15, 26). These T cells,
which recognized in an HLA class I–restricted manner the au-
tologous CICs (Fig. 4A–C), displayed a recognition of the COA-
1–derived epitopes (Fig. 4D). Of note, for patients #1076 and
14583 (both HLA-A24 positive) an efficient reactivity was found
against the HLA-A24–binding COA-1 peptide loaded on HLA-
matched allogeneic 1869 EBV-B cells (15, 16). Moreover, MLTCs
from HLA-A2+ patient #1247 specifically (HLA class I restricted)
recognized the HLA-matched T2 cells preincubated with the HLA-
A*0201–binding COA-1 epitope (16). Notably, the COA-1 reac-
tivity of these MLTCs was increased by blocking IL-4 with the
neutralizing mAb (Fig. 4D). In addition, higher levels of COA-1
reactivity were observed with MLTCs stimulated in vitro with CICs
than with MLTCs stimulated with FBS tumor cells.
These results indicate that CICs can act as stimulators when the
expression of MHC and APM is upregulated, although not at
optimal levels, by IFN-g treatment and can efficiently activate
COA-1–specific T cells. The extent of COA-1 recognition by these
T cells was heterogeneous in the three patients studied, perhaps
depending on the patient’s efficiency of Ag processing and/or on
the TCR avidity of T cells. Recognition of other CRC-associated
Ags, such as SVV-1, NY-ESO-1, IL13Ra2, and Ep-CAM, by
T cells was not observed (data not shown).
The IF and cytofluorimetric or confocal microscopy analyses of
a panel of TAAs previously reported as expressed by CRC (e.g.,
MAGE, NY-ESO-1, Gp100, SVV-1, COA-1, and IL-13Ra2) (15–
26) revealed that all CICs and FBS tumor cells from patients 1076,
1247, 111011 and 14583 were negative for MAGE and Gp100 and
expressed low levels (MRFI = 2–4) of NY-ESO-1 and IL-13Ra2
(data not shown). Sox2, Ep-CAM, and CEA, which in addition to
their role as markers associated with CICs or CRC-derived CICs
(Supplemental Fig. 2A) represent target molecules of T cell
responses (26), were found to be upregulated in CICs compared
with FBS tumor cells. Of interest, COA-1 (Supplemental Fig. 1N,
1O) and, to a lesser extent, SVV-1 (Supplemental Fig. 1 P–Q)
were clearly expressed with both nuclear and cytoplasmic local-
izations in 100% of the evaluated CICs (Supplemental Fig. 1N,
and 1P, respectively) and FBS tumor cells (Supplemental Fig. 1O,
1Q, respectively), with the SVV-1 expressed more homogeneously
by CICs than by FBS tumor cells.
Therefore, for the first time, to our knowledge, we could identify
a novel candidate TAA (COA-1) that can be targeted by T cell
responses directed against CRC CICs.
Discussion
The existence within human CRCs of a subpopulation of cancer
cells with tumor intiating/stem-like properties has been widely
documented (1–3, 20–24). However, the detailed characterization
and identification of the CIC antigenic/immunogenic profile have
not yet been accomplished. In the present work we have isolated
from seven primary CRCs a subpopulation of cells growing as
spheres and displaying CIC properties, as shown by the over-
expression of CRC- and CIC-associated markers and by the in vivo
high tumorigenicity. Moreover, for three CRC patients also the au-
tologous differentiated tumor cell counterparts of the tumor (i.e., FBS
cells) were isolated in vitro. This strategy of isolating two different
subpopulations of tumor cells from the same clinical sample has been
previously reported in the GBM model (10, 17, 18).
Table II. IL-4 neutralization can augment the proliferation of MLTCs stimulated with autologous CICs
T Cells Mitogen Tumor Cells Proliferation Indexa
MLTC No No 1.24 (0.29)
PHA/Con A No 2.25 (0.23)
PHA/Con A CICs 1.45 (0.59)
CICs + anti–IL-4 2.50 (0.34)
MLTC + anti-IL-4 No No 1.40 (0.30)
PHA/Con A No 2.40 (0.56)
PHA/Con A CICs 1.90 (0.26)
CICs + anti–IL-4 3.08 (0.49)
T Cells Mitogen Treatment Proliferation Indexa
IL-4– + IL-2–dependent growth No No 1.2
PHA/Con A No 4
PHA/Con A + Anti–IL-4 2.4
+ Anti–IL-4R 2.7
+ Anti–IL-4 + anti–Il-4R 1.5
A total of 1 3 107 T cells from MLTCs of CRC patients #1076, 1247, and 14583 were stained with 1 mM CSFE and
stimulated with PHA/Con A in the presence or not of 3-d cultured CICs pretreated or not with 10 mg/ml of anti–IL-4 mAb.
Then, cells were harvested and the CFSE profile was assessed by flow cytometry. Data are referred to CD3+ gated cells and
represent the mean of the proliferation index of the three patients; the number in parentheses is the SD.
aThe Proliferation Index is the total number of divisions divided by the number of cells that went into division. The
efficiency of neutralization of IL-4 and IL-4R by the specific mAbs was determined in performing CFSE staining and
proliferation assay on PBMCs from healthy donors that were cultured in vitro for 5 d in the presence of 100 IU of IL-2 and
10 ng/ml of IL-4. Bold data represent the percent of divided cells or the proliferation index of the positive controls or of rescued
values following the neutralization of IL-4.
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A high degree of heterogeneity in CIC phenotype can be found
likely owing to modulation by different factors, including genetic
background, epigenetic modifications, and tumor–microenviron-
ment interactions (27, 28). Thus far, a failure in the identification
of CIC-specific markers precluded the use of a unique method for
ex vivo isolation and characterization of these cells. Surrogate
markers associated with stem cell properties, such as CD133,
CD24, CD44, and ALDH-1, have been commonly used for CRC
CIC detection, although controversial results with the stem cell
properties of these cells have been reported (1, 2, 21–23, 29).
More recently for the first time a potential stem cell–specific
marker, Lgr5, has been identified for both normal and tumor co-
lorectal tissues (24). Of interest, our sphere-forming cells were
homogeneously positive for the expression of this molecule, thus
indicating that indeed these cells displayed CIC properties. Con-
versely, FBS tumor cells were almost negative for this marker and
showed lower tumorigenic properties than did CICs, although on
the basis of the heterogeneity and plasticity of tumor cells we
cannot rule out that these cells can modulate in vivo their phe-
notypic and functional state.
A detailed immune profile characterization of CRC-derived
CICs and FBS tumor cells was carried out to assess whether
these cells can be targeted by immunotherapy. We found a weak
immunogenicity of CICs compared with autologous FBS tumor
cells because MHC and APM molecules were preferentially
downmodulated in the CICs. Moreover, IFN (a or g) and the
demethylating agent (5-Aza CdR) were not or only weakly ef-
fective as modulators of these molecules (data not shown). Along
with the low immunogenicity of the CRC-derived CICs, we found
that these cells can play a role in the modulation of T cell–me-
diated responses. In fact, proliferation of T cells was inhibited by
coculture with autologous or allogeneic CICs, but not with FBS
tumor cells. CIC-associated factors, such as TGF-b, IL-10, IL-13,
galectin, and PDGE2, which can play a negative regulatory role in
the induction of tumor reactive T cells, have been described (12–
14) and, notably, shown to be shared with normal stem cells as
well (30). The complexity of this issue is demonstrated by the
evidence that none of the molecules described above have been
found to be specifically expressed or upregulated in CICs that we
have isolated in vitro (data not shown), in line with the results that
have been previously published by our group for GBM (10).
Along this line, we found that the membrane expression of IL-4
and, to a lesser extent, of IL-4R, was preferentially associated with
CICs rather than with FBS tumor cells. Studies on the expression
of this molecule by CRC CICs have been previously published,
demonstrating that these cells, by the autocrine production of IL-4,
protect themselves from apoptosis and acquire resistance to che-
motherapy (19, 25). The novelty of our findings is that CIC-
associated IL-4 mediates the inhibition of T cell proliferation in
the coculture of PBMCs from either CRC patients or healthy donors
with autologous or allogeneic CICs (6/6 CRC patients). Of note,
this phenomenon was shown to be dependent on cell-to-cell contact
between CICs and T cells. In fact, coculture without cellular contact
of T lymphocytes with the CICs or with CIC-derived cell culture
supernatants did not affect their proliferation (Table I and data not
shown). Moreover, we demonstrated that the proliferation of T cells
was only partially affected by the CIC-secreted IL-4.
The negative immunomodulatory activity of CICs is not me-
diated by the autocrine engagement of IL-4 signaling, contrary to
the chemotherapy resistance pathway of these cells (19, 25), be-
cause the neutralization of IL-4R on CICs failed to restore T cell
proliferation. Thus this CIC function is mostly dependent on the
engagement of the IL-4R on T cells by the CIC-associated specific
ligand. Of note, the phenotype of MLTC-derived T cells, showing
a skew toward the preferential enrichment of Th1-type CD8+
T cells, was also affected by IL-4 blocking. A total of 34% of NK
cells could be detected in the MLTC from one CRC patient
stimulated with CICs. This evidence is in line with the reported
observation that NK cell susceptibility was higher in CRC CICs
than in FBS tumor cells, correlating with higher expression and
lower levels by CICs of NK receptor ligands and MHC class I
molecules, respectively (31). Of interest, by the neutralization of
IL-4 signaling, the MLTC showed enrichment of CD8+ T cells,
indicating that the blocking of IL-4 can prevent one of the immu-
nosuppressive mechanisms associated with CICs and can switch the
tumor–lymphocyte interaction supporting activation and prolifera-
tion of T rather than NK cells. Thus, IL-4 represents one of the
key molecules that regulate CIC-associated immunomodulatory
activity, and therapeutic approaches based on the neutralization of
this molecule should be sought. Additional mechanisms of immu-
nosuppression associated with CICs need to be investigated in the
future to obtain a more detailed immunological profile of these
cells. IL-4 signaling blockade in vivo has been shown to reprogram
tumor-associated macrophages and to inhibit their proangiogenic
and tumorigenic activities (32). IL-4/IL-13 and their receptors have
been shown to be expressed by epithelial tumors and to represent
potential players in tumor behavior and in its responsiveness to
standard therapeutic interventions (33). Nevertheless, these mole-
cules are critical regulators of immune responses. On the basis of
our results, the blocking of IL-4 signaling affects T cell–mediated
tumor reactivity, leading to the skew toward T cell effector
responses and to the induction of efficient anti-CIC immune
responses. This issue needs to be further investigated in vivo by
immunotherapy-based experiments developed in mouse models;
however, interventions aimed at blocking IL-4 signaling may re-
sult in novel immune-based therapeutic targeting of CRC CICs.
Another key observation of this study is the identification of
a target molecule recognized by CIC-specific T cells. We found that
COA-1 (15, 16) was recognized in vitro by T cells from three CRC
patients (#1076, 1247, and 14573), isolated by MLTCs whose
autologous CICs represented the source of Ags. We failed to detect
T cell responses against T cell epitopes deriving from CRC-
associated SVV-1, NY-ESO-1, and IL-13Ra2 (data not shown).
Surprisingly, although FBS tumor cells also expressed COA-1
(Supplemental Fig. 1O), CICs could elicit anti–COA-1 T cell
responses more efficiently than could FBS tumor cells. This finding
suggests that IFN-g treatment of CICs can induce the secretion of
immunomodulatory factors such as IL-4 (Fig. 2B) but can also ac-
tivate the APM to induce T cell responses against highly expressed
TAAs endowed with strong immunogenic potency, such as COA-1
(16). The limiting factor of this type of experiment is the need for an
autologous setting and thus the availability from the same patients of
CICs, PBMCs. and, possibly, FBS tumor cells. The limited avail-
ability of these biological samples from all CRC patients prevented us
from investigating a larger number of subjects. Nevertheless, our
results suggest that COA-1 may represent a target molecule for T cell
responses against CRC CICs. In future studies it would be worthwhile
to investigate the mechanisms that can lead to differential COA-1
processing and presentation in CICs compared with FBS tumor cells.
Of note, the COA-1–mediated reactivity associated with CICs in-
versely correlated with the levels of expression and secretion of IL-4
(see results in Fig. 2B, Fig. 4) and was augmented in the presence of
neutralizing IL-4 mAb.
COA-1 has not been extensively studied for clinical treatments of
CRC patients; however, circulating T cells, both CD4+ and CD8+,
directed to this Ag could be isolated from CRC patients, indicating
its relevance as a target molecule for immunotherapy for this
disease. Thus, the results provided by the present work may have
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relevant implications for the design of new combined immuno-
therapy for CRC, based on active vaccination plus an immuno-
modulatory agent to target CRC CICs.
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